Elevation of plasma phenytoin by viloxazine in epileptic patients: A clinically significant drug interaction

F. Pisani, A. Fazio, C. Artesi, M. Russo, R. Trio, G. Oteri, E. Perucca, R. Di Perri

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The effect of viloxazine (150-300 mg daily for 21 days) on plasma phenytoin levels at steady state was examined in 10 epileptic patients stabilised on a fixed phenytoin dosage. After starting viloxazine treatment, plasma phenytoin concentrations increased by 37% on average (range 7-94%) from a mean value of 18.8, μg/ml at baseline to a mean value of 25.7 μg/ml during the last week of combined therapy. In four patients the rise in plasma phenytoin was associated with the development of signs of phenytoin toxicity. Discontinuation of viloxazine resulted in return of plasma phenytoin towards baseline values and disappearance of the clinical symptoms. The mechanism of interaction probably involves inhibition of phenytoin metabolism by viloxazine. Careful monitoring of plasma phenytoin levels is recommended in patients treated with phenytoin who need to be started on viloxazine therapy.

Original languageEnglish
Pages (from-to)126-127
Number of pages2
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume55
Issue number2
Publication statusPublished - 1992

Fingerprint

Viloxazine
Phenytoin
Drug Interactions
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Pisani, F., Fazio, A., Artesi, C., Russo, M., Trio, R., Oteri, G., ... Di Perri, R. (1992). Elevation of plasma phenytoin by viloxazine in epileptic patients: A clinically significant drug interaction. Journal of Neurology, Neurosurgery and Psychiatry, 55(2), 126-127.

Elevation of plasma phenytoin by viloxazine in epileptic patients : A clinically significant drug interaction. / Pisani, F.; Fazio, A.; Artesi, C.; Russo, M.; Trio, R.; Oteri, G.; Perucca, E.; Di Perri, R.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 55, No. 2, 1992, p. 126-127.

Research output: Contribution to journalArticle

Pisani, F, Fazio, A, Artesi, C, Russo, M, Trio, R, Oteri, G, Perucca, E & Di Perri, R 1992, 'Elevation of plasma phenytoin by viloxazine in epileptic patients: A clinically significant drug interaction', Journal of Neurology, Neurosurgery and Psychiatry, vol. 55, no. 2, pp. 126-127.
Pisani, F. ; Fazio, A. ; Artesi, C. ; Russo, M. ; Trio, R. ; Oteri, G. ; Perucca, E. ; Di Perri, R. / Elevation of plasma phenytoin by viloxazine in epileptic patients : A clinically significant drug interaction. In: Journal of Neurology, Neurosurgery and Psychiatry. 1992 ; Vol. 55, No. 2. pp. 126-127.
@article{4c424eab0c6d4410b313265ad16d05f3,
title = "Elevation of plasma phenytoin by viloxazine in epileptic patients: A clinically significant drug interaction",
abstract = "The effect of viloxazine (150-300 mg daily for 21 days) on plasma phenytoin levels at steady state was examined in 10 epileptic patients stabilised on a fixed phenytoin dosage. After starting viloxazine treatment, plasma phenytoin concentrations increased by 37{\%} on average (range 7-94{\%}) from a mean value of 18.8, μg/ml at baseline to a mean value of 25.7 μg/ml during the last week of combined therapy. In four patients the rise in plasma phenytoin was associated with the development of signs of phenytoin toxicity. Discontinuation of viloxazine resulted in return of plasma phenytoin towards baseline values and disappearance of the clinical symptoms. The mechanism of interaction probably involves inhibition of phenytoin metabolism by viloxazine. Careful monitoring of plasma phenytoin levels is recommended in patients treated with phenytoin who need to be started on viloxazine therapy.",
author = "F. Pisani and A. Fazio and C. Artesi and M. Russo and R. Trio and G. Oteri and E. Perucca and {Di Perri}, R.",
year = "1992",
language = "English",
volume = "55",
pages = "126--127",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Elevation of plasma phenytoin by viloxazine in epileptic patients

T2 - A clinically significant drug interaction

AU - Pisani, F.

AU - Fazio, A.

AU - Artesi, C.

AU - Russo, M.

AU - Trio, R.

AU - Oteri, G.

AU - Perucca, E.

AU - Di Perri, R.

PY - 1992

Y1 - 1992

N2 - The effect of viloxazine (150-300 mg daily for 21 days) on plasma phenytoin levels at steady state was examined in 10 epileptic patients stabilised on a fixed phenytoin dosage. After starting viloxazine treatment, plasma phenytoin concentrations increased by 37% on average (range 7-94%) from a mean value of 18.8, μg/ml at baseline to a mean value of 25.7 μg/ml during the last week of combined therapy. In four patients the rise in plasma phenytoin was associated with the development of signs of phenytoin toxicity. Discontinuation of viloxazine resulted in return of plasma phenytoin towards baseline values and disappearance of the clinical symptoms. The mechanism of interaction probably involves inhibition of phenytoin metabolism by viloxazine. Careful monitoring of plasma phenytoin levels is recommended in patients treated with phenytoin who need to be started on viloxazine therapy.

AB - The effect of viloxazine (150-300 mg daily for 21 days) on plasma phenytoin levels at steady state was examined in 10 epileptic patients stabilised on a fixed phenytoin dosage. After starting viloxazine treatment, plasma phenytoin concentrations increased by 37% on average (range 7-94%) from a mean value of 18.8, μg/ml at baseline to a mean value of 25.7 μg/ml during the last week of combined therapy. In four patients the rise in plasma phenytoin was associated with the development of signs of phenytoin toxicity. Discontinuation of viloxazine resulted in return of plasma phenytoin towards baseline values and disappearance of the clinical symptoms. The mechanism of interaction probably involves inhibition of phenytoin metabolism by viloxazine. Careful monitoring of plasma phenytoin levels is recommended in patients treated with phenytoin who need to be started on viloxazine therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026499882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026499882&partnerID=8YFLogxK

M3 - Article

C2 - 1538217

AN - SCOPUS:0026499882

VL - 55

SP - 126

EP - 127

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 2

ER -